Biography                                                                                                                                                                                                                                                   

Born in Basingstoke, Hampshire, I was educated at The Vyne School and Queen Marys College before going onto study at the School of Medicine at The University of Manchester. Here I obtained a 1st Class Honours degree in Anatomy followed by my primary medical degree (MB.ChB.). After gaining my Fellowship of the Royal College of Surgeons I undertook a period of research at the Cancer Research UK Laboratories (Paterson Institute for Cancer Research/Christie Hospital) in Manchester. Here I undertook research in the treatment of bladder cancer, which led to the award of a Doctorate of Medicine (MD). I subsequently trained in General Urology in the North West of England and then undertook specialist training in Urological Cancer management at the Christie Hospital during which I obtained my Certificate of Specialist Training and my Specialist Urological Fellowship of The Royal College of Surgeons. In addition to this I spent a short period working at the Royal Surrey County Hospital learning Minimally Invasive Surgery and also attended the University Louis Pastuer, Strasburg, France , where I obtained a Diploma in Laparoscopic Surgery. I then took up my post as Consultant Urological Surgeon/Urologist at The Christie Hospital and University Hospital of South Manchester.

I specialise in Penile surgery with some reconstructive work; being the Lead Clinician in the North West; this involves an element of dealing with Sexual Dysfunction. This has led to the development of an interest in Male Infertility Surgery using modern techniques. I also manage Bladder and Prostate Cancer, and offer keyhole surgery for Kidney Cancer; I have developed a specialist interest in New Technologies for the treatment of these conditions.

I am active in research, having published in journals and presented my research internationally. 

GMC Number: 4013107

Current NHS Posts

Consultant Urological Surgeon
The Christie Hospital NHS Foundation Trust
Manchester UK

Consultant Urological Surgeon
University Hospital of South Manchester NHS Foundation Trust
Manchester UK

Hon Senior Lecturer, Imaging & Cancer studies, University of Manchester, UK

Other Posts

Member NCRI Penile Cancer Studies Sub-Group

Member RCS Penile Cancer Sentinel Node Steering Committee

Associations & Societies

British Medical Association
British Association of Urological Surgeons
European Association of Urology
British Prostate Group/BAUS Section of Oncology
New York Academy of Sciences & The European and The International Society of Sexual Medicine

 
Publications 

Bromage SJ, Douglas J, Sangar VK, Falconer D & Payne SR. Surgical sperm retrieval rates for assisted conception in men with primary and secondary azospermia. Eur Urol. 2007 Feb;51(2):534-9; discussion 539-40. Epub 2006 Sep 5.
 
Nathaniel C., Sangar VK. & Payne SR. A 15 year longitudinal analysis of trends in elective urological surgery – An evidence base for Modernising Medical careers.
Ann R Coll Surg Engl. 2007 Mar;89(2):157-61.
   
Clarke NW, Sangar VK. Urine telomerase activity for the diagnosis of bladder cancer. Nat Clin Pract Urol. 2006 Apr;3(4):192-3.
 
Sangar VK, McBain C, Lyons J, Ramani VAC, Wylie J, Logue J, Clarke NW & Cowan R. A phase I study of radiochemotherapy with gemcitabine and conformal radiotherapy in the treatment of locally invasive bladder cancer. Int J Radiation Oncology Biology Physics. 2005 Feb 1; 61(2): 420-5.
 
Ragavan N, Sangar VK, Gupta S, Matanhelia SS, Watson ME & Blades RA. Is DRE essential for the follow-up of prostate cancer patients: a prospective audit of 194 patients. BMC Urology. 2005 Jan 10; 5(1):1.
 
Sangar VK, Ragavan N, Matanhelia SS, Watson ME & Blades RA. The Economic consequences of prostate and bladder cancer in the UK. BJU Int 2005 Jan; 95(1):59-63.
 
Madaneni S, Sangar VK, Hendry J, Margison GP & Clarke NW. Differential radiosensitision by ZD 1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in related bladder cancer cell lines. Br J Cancer 2005 Jan 17; 92(1):125-30.
 
Sangar VK, Cowan R, Margison GP, Hendry JH & Clarke NW.
An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines. Br J Cancer. 2004 Jan 26;90(2):542-8.
 
Kassem Sh. H, Sangar VK, Cowan R, Clarke NW & Margison GP. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer. 2002 Oct 10;101(5):454-60
 
Collis SJ, Sangar VK, Tighe A, Roberts SA, Clarke NW, Hendry JH & Margison GP.
Development of a novel rapid assay to assess the fidelity of DNA double strand break repair in human tumour cells. Nucleic Acid Research Methods 2002 Jan 15;30(2):E1.
 
Sangar VK, Saidi S, Fisher C & O'Brien T.
Lymphadenopathy in a patient with carcinoma of the Penis: A feline diagnosis. British Journal of Urology 1999 Dec 84(9):1111-2.
 
Sangar VK. Responses of normal and hypertrophying mouse skeletal muscle to low dose growth hormone treatment. Journal of Anatomy 1991 176:233.
 
Mahon M, Sangar VK, Liderth SA & Kristmundsdottir F. Effects of therapeutic doses of growth hormone on mouse skeletal muscle. Journal of Anatomy 1990 173:213.

Sangar VK. Texts... www.Review. Urology News 2004 March/April.
 
Sangar VK. Talking BPH. www.Review. Urology News 2003 Sept/Oct.
 
Sangar VK. Synergo. www.Review. Urology News 2003 June.
 
Sangar VK. Prostatitis. www.Review. Urology News 2003 March/April.
 
Sangar VK. Andropause. www.Review. Urology News 2002 6(6):22.
 
Sangar VK. Patient Education. www.Review. Urology News 2002 6(5):18.
 
Sangar VK. Globalisation and Urology. www.Review. Urology News 2002 6(4):22.
 
Sangar VK. Improving Working Lives. www.Review. Urology News 2002 6(3):22.
 
Sangar VK. Human Rights & Informed Consent. www.Review. Urology News 2002 6(2):22.
 
Sangar VK. Galleries of Urology. www.Review. Urology News 2002 6(1):22.
 
Sangar VK. Laparoscopic Urology. www.Review. Urology News 2001 5(7):22.
 
Sangar VK. Radiofrequency for Stress Incontinence. www.Review. Urology News 2001 5(6):20.
 
Sangar VK. CPD and Revalidation: Urology. www.Review. Urology News 2001 5(5):26.

Awards
 
European Association of Urology Congress Best Poster Presentation (session).
Salvage orchidectomy post chemotherapy patients. Paris, France. March 2007.
 
BUF Clinical Visit Fellowship to The Netherlands Cancer Institute, Amsterdam to work with Prof S. Horenblas a world renowned penile cancer expert. Jan 2007.
 
European Association of Urology Congress Best Poster Presentation (session).
The Economic consequences of prostate and bladder cancer in the UK. Istanbul, Turkey. March 2005.
 
European Association of Urology Congress Best Poster Presentation (session).
Differential radiosensitisation of bladder cancer cell lines by Gemcitabine and its relationship to p53 status and cell cycle perturbations. Birmingham, UK. February 2002.
 
European Association of Urology Congress Best Poster Presentation (session).
Differential gene expression of bladder cancer cell lines with different radiosensitivity using Atlas cDNA arrays . Birmingham, UK. February 2002.
 
Global Lilly Young Investigators Translational/Pharmacogenomics Research Award.
Targeting the radiosensitising effects of Gemzar: A pharmacogenomic based in-vitro study. Natural History Museum, London, UK. December 2001.
 
AACR-NCI-EORTC International Conference. Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications. Astra Zeneca Best Poster Prize. A potential role of HSPs and a novel gene: NNMT in predicting response to radiation in bladder cancer. October 2001.
 
British Association of Cancer Research Annual Meeting Best Poster Prize. A rapid dual-fluorescence DNA misrepair assay for predicting radiosensitivity in urological cancer cell lines. Leeds, UK. July 2001.
 
European Association of Urology Congress Best Poster Presentation (session). Predicting radiosensitivity of urological tumours using a rapid dual-fluorescence Assay for DNA misrepair. Geneva, Switzerland. April 2001.

I have given numerous national and international presentations and lectures.